Evidence map›Paper›PMID 29293566›Full record

ArticlePloS one2018

High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns.

Zizipho Z A Mbulawa, Cari van Schalkwyk, Nai-Chung Hu, Tracy L Meiring, Shaun Barnabas, Smritee Dabee, Heather Jaspan, Jean-Mari Kriek, Shameem Z Jaumdally, Etienne Muller and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Cervical Cancer Screening and Treatment Algorithms Using Human Papillomavirus Testing-Lessons Learnt from a South African Pilot Randomized Controlled Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 4 countries.

Zizipho Z A MbulawaInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Cari van SchalkwykThe South African Department of Science and Technology/National Research Foundation Centre of Excellence in Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa.
Nai-Chung HuInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Tracy L MeiringInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Shaun BarnabasInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Smritee DabeeInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Heather JaspanInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Jean-Mari KriekInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Shameem Z JaumdallyInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Etienne MullerCenter for HIV and STIs, National Institute for Communicable Disease, National Health Laboratory Service, Johannesburg, South Africa.
Linda-Gail BekkerInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
David A LewisWestern Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia.
Janan DietrichPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Diepkloof, Johannesburg, South Africa.
Glenda GrayPerinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Diepkloof, Johannesburg, South Africa.
Jo-Ann S PassmoreInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Anna-Lise WilliamsonInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-5467-1200
University of Cape Town · ZANational Health Laboratory Service · ZADesmond Tutu HIV Foundation · ZASeattle Children's Hospital · USSouth African Medical Research Council · ZAStellenbosch University · ZAThe University of Sydney · AUUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objectives of the study were to investigate prevalence of cervical human papillomavirus (HPV) genotypes to inform HPV vaccination strategy in South Africa and to study factors associated with HPV prevalence. Sexually active, HIV-negative women, aged 16-22 years recruited from Soweto (n = 143) and Cape Town (n = 148) were tested for cervical HPV and other genital infections. Overall HPV prevalence was 66.7% (194/291) in young women. Cape Town women were more likely to have multiple HPV infections than the Soweto women (48.0%, 71/148 versus 35.0%, 50/143 respectively, p = 0.033) and probable HR-HPV types (34.5%, 51/148 versus 21.7%, 31/143 respectively, p = 0.022). The most frequently detected HPV types were HPV-16 (11.7%), HPV-58 (10.3%), HPV-51 (8.9%), HPV-66 (8.6%), HPV-18 and HPV-81 (7.6% each). HPV types targeted by the bivalent HPV vaccine (HPV-16/18) were detected in 18.6% (54/291) of women, while those in the quadrivalent vaccine (HPV-6/11/16/18) were detected in 24.7% (72/291) of women; and those in the nonavalent vaccine (HPV-6/11/16/18/31/33/45/52/58) were detected in 38.5% (112/291) of women. In a multivariable analysis, bacterial vaginosis remained significantly associated with HPV infection (OR: 4.0, 95% CI: 1.4-12.6). Women were more likely to be HPV positive if they had received treatment for STI during the past 6-months (OR: 3.4, 95% CI: 1.1-12.4) or if they had ever been pregnant (OR: 2.3, 95% CI: 1.1-5.5). Compared to women who reported only one sexual partner, those with increased number of lifetime sex partners were more likely to have HPV (4-10 partners: OR: 2.9, 95% CI: 1.1-8.0). The high prevalence of HPV types targeted by the nonavalent HPV vaccine encourages the introduction of this vaccine and catch-up HPV vaccination campaigns in South Africa. The high burden of BV and concurrent STIs also highlights the need to improve the prevention and appropriate management of sexually-acquired and other genital tract infections in South African youth.

Indexed as

AdolescentAdultAlphapapillomavirusFemaleHumansPapillomavirus InfectionsPapillomavirus VaccinesPrevalenceSouth AfricaYoung AdultPapillomavirus Vaccines

Identifiers

PMID29293566
PMCPMC5749739
OpenAlexW2781918956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.